JP2014509851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509851A5 JP2014509851A5 JP2013557704A JP2013557704A JP2014509851A5 JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5 JP 2013557704 A JP2013557704 A JP 2013557704A JP 2013557704 A JP2013557704 A JP 2013557704A JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5
- Authority
- JP
- Japan
- Prior art keywords
- npp1
- fusion protein
- npp1 fusion
- acid residues
- targeting moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34006610P | 2010-03-12 | 2010-03-12 | |
| USPCT/US2011/028233 | 2011-03-11 | ||
| PCT/US2011/028233 WO2011113027A2 (en) | 2010-03-12 | 2011-03-11 | Npp1 fusion proteins |
| PCT/US2011/051858 WO2012125182A1 (en) | 2011-03-11 | 2011-09-15 | Npp1 fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015084216A Division JP6096826B2 (ja) | 2010-03-12 | 2015-04-16 | Ｎｐｐ１融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509851A JP2014509851A (ja) | 2014-04-24 |
| JP2014509851A5 true JP2014509851A5 (enExample) | 2014-11-06 |
| JP5735665B2 JP5735665B2 (ja) | 2015-06-17 |
Family
ID=44564171
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557704A Active JP5735665B2 (ja) | 2010-03-12 | 2011-09-15 | Ｎｐｐ１融合タンパク質 |
| JP2015084216A Active JP6096826B2 (ja) | 2010-03-12 | 2015-04-16 | Ｎｐｐ１融合タンパク質 |
| JP2017026961A Active JP6484905B2 (ja) | 2010-03-12 | 2017-02-16 | Ｎｐｐ１融合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015084216A Active JP6096826B2 (ja) | 2010-03-12 | 2015-04-16 | Ｎｐｐ１融合タンパク質 |
| JP2017026961A Active JP6484905B2 (ja) | 2010-03-12 | 2017-02-16 | Ｎｐｐ１融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US8846603B2 (enExample) |
| EP (1) | EP2545080B1 (enExample) |
| JP (3) | JP5735665B2 (enExample) |
| BR (1) | BR112013023010B1 (enExample) |
| CL (1) | CL2013002607A1 (enExample) |
| ES (2) | ES2628841T3 (enExample) |
| NZ (1) | NZ615070A (enExample) |
| SG (2) | SG10201500208SA (enExample) |
| TR (1) | TR201903573T4 (enExample) |
| WO (1) | WO2011113027A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545080B1 (en) | 2010-03-12 | 2017-05-10 | Alexion Pharmaceuticals, Inc. | Npp1 fusion proteins |
| BR122019021757B1 (pt) | 2010-09-09 | 2020-12-08 | Alexion Pharmaceuticals, Inc | composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal) |
| EP2675472A4 (en) | 2011-02-15 | 2014-09-17 | Synageva Biopharma Corp | METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE |
| EP2683742B1 (en) * | 2011-03-11 | 2018-12-19 | Alexion Pharmaceuticals, Inc. | Npp1 fusion proteins |
| PL2956163T3 (pl) | 2013-02-13 | 2025-04-14 | Yale University | Kompozycje do leczenia patologicznego zwapnienia i kostnienia |
| EP2994759B1 (en) * | 2013-05-06 | 2018-09-12 | Bio-rad Laboratories, Inc. | Stabilization of labile analytes in reference materials |
| HK1245662A1 (zh) * | 2014-12-19 | 2018-08-31 | Alexion Pharmaceuticals, Inc. | 治疗组织钙化的方法 |
| EP3298140B1 (en) | 2015-05-19 | 2024-04-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| EP3377105A4 (en) | 2015-11-20 | 2019-04-24 | Yale University | COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH |
| EP3471747A1 (en) * | 2016-06-16 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| US11390859B2 (en) | 2016-08-05 | 2022-07-19 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| EP3844280A4 (en) * | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
| US11834512B2 (en) * | 2020-05-04 | 2023-12-05 | The Regents Of The University Of California | Inhibiting anti-ENPP1 antibodies |
| EP4162036A1 (en) | 2020-06-09 | 2023-04-12 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| CA3184349A1 (en) * | 2020-07-02 | 2022-01-06 | Damon BANKS | Compositions and methods for treating allograft vasculopathy, moyamoya disease, moyamoya syndrome and intimal proliferation |
| WO2025184419A1 (en) * | 2024-02-29 | 2025-09-04 | Kodiak Sciences Inc. | Engineered complement inhibitor proteins |
| WO2026102337A1 (en) | 2024-11-08 | 2026-05-15 | Biomarin Pharmaceutical Inc. | Enpp1 for use in the treatment of calciphylaxis |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
| CA2280957A1 (en) | 1997-02-14 | 1998-08-20 | Leslie Orgel | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| AU752946B2 (en) | 1997-10-16 | 2002-10-03 | Avigenics, Inc. | Vectors comprising a magnum-specific promoter for avian transgenesis |
| US20040019923A1 (en) | 1997-10-16 | 2004-01-29 | Ivarie Robert D. | Exogenous proteins expressed in avians and their eggs |
| PT1032662E (pt) | 1997-11-07 | 2006-07-31 | Trillium Therapeutics Inc | Metodos e composicoes para imunomodulacao. |
| DE20121960U1 (de) * | 2000-04-06 | 2004-01-15 | Epigenomics Ag | Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten |
| US20020108132A1 (en) | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
| WO2003072593A2 (en) | 2002-02-21 | 2003-09-04 | University Of Virginia Patent Foundation | Bone targeting peptides |
| US20050090001A1 (en) | 2003-10-07 | 2005-04-28 | Parker Stephen H. | Cell lines and methods for producing proteins |
| PL1759001T3 (pl) | 2004-04-21 | 2011-09-30 | Alexion Pharma Inc | Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości |
| US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US20090180989A1 (en) * | 2005-10-05 | 2009-07-16 | Synageva Biopharma Corp. | Compositions and methods for delivering nucleotide sequences to vertebrates |
| DK2662448T3 (en) | 2007-05-11 | 2017-03-20 | Alexion Pharma Inc | Bone-targeted alkaline phosphatase, kits and methods for its use |
| AR071885A1 (es) * | 2008-05-23 | 2010-07-21 | Wyeth Corp | Proteinas de union al receptor de interleuquina 21 |
| EP2545080B1 (en) | 2010-03-12 | 2017-05-10 | Alexion Pharmaceuticals, Inc. | Npp1 fusion proteins |
-
2011
- 2011-03-11 EP EP11754231.6A patent/EP2545080B1/en active Active
- 2011-03-11 US US13/583,973 patent/US8846603B2/en active Active
- 2011-03-11 WO PCT/US2011/028233 patent/WO2011113027A2/en not_active Ceased
- 2011-03-11 ES ES11754231.6T patent/ES2628841T3/es active Active
- 2011-09-15 ES ES11861101T patent/ES2716526T3/es active Active
- 2011-09-15 SG SG10201500208SA patent/SG10201500208SA/en unknown
- 2011-09-15 US US14/004,294 patent/US20140154774A1/en not_active Abandoned
- 2011-09-15 TR TR2019/03573T patent/TR201903573T4/tr unknown
- 2011-09-15 JP JP2013557704A patent/JP5735665B2/ja active Active
- 2011-09-15 NZ NZ615070A patent/NZ615070A/en not_active IP Right Cessation
- 2011-09-15 BR BR112013023010-0A patent/BR112013023010B1/pt active IP Right Grant
- 2011-09-15 SG SG10202100341XA patent/SG10202100341XA/en unknown
-
2013
- 2013-09-10 CL CL2013002607A patent/CL2013002607A1/es unknown
-
2014
- 2014-08-01 US US14/449,364 patent/US9540621B2/en active Active
- 2014-10-06 US US14/507,124 patent/US20150024460A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084216A patent/JP6096826B2/ja active Active
-
2017
- 2017-01-27 US US15/417,590 patent/US20170145393A1/en not_active Abandoned
- 2017-02-16 JP JP2017026961A patent/JP6484905B2/ja active Active
-
2020
- 2020-11-25 US US17/105,245 patent/US20210301268A1/en not_active Abandoned
-
2022
- 2022-08-11 US US17/819,065 patent/US20230129977A1/en not_active Abandoned
-
2025
- 2025-04-18 US US19/183,431 patent/US20260022356A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2342669T3 (es) | Adzimas y usos de las mismas. | |
| NZ615070A (en) | Npp1 fusion proteins | |
| JP2005120106A5 (enExample) | ||
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| JP2012522501A5 (enExample) | ||
| JP2016527891A5 (enExample) | ||
| JP2010068806A5 (enExample) | ||
| JP2015525217A5 (enExample) | ||
| HRP20161531T1 (hr) | Fc fuzijski proteini koji sadrže nove linkere ili aranžmane | |
| JP2017018125A5 (enExample) | ||
| JP2018033454A5 (enExample) | ||
| RU2011137003A (ru) | Полипептиды, обладающие целлюлазной активностью | |
| JP2015212284A5 (enExample) | ||
| RS64002B1 (sr) | Anti-kancerski fuzioni polipeptid | |
| RU2018117558A (ru) | Слитые иммуномодулирующие белки и способы их получения | |
| JP2010273685A5 (enExample) | ||
| JP2019527200A5 (enExample) | ||
| HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
| JP2008301828A5 (enExample) | ||
| JP2014510518A5 (enExample) | ||
| JP2017512063A5 (enExample) | ||
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih | |
| FI2968461T3 (fi) | Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi | |
| JP2012095652A5 (enExample) | ||
| JP2011501971A5 (enExample) |